PURPOSE: Acute skin toxicity is one of the most common side effects of breast cancer radiotherapy. To date, no one has estimated the nonmedical out-of-pocket expenses associated with this side effect. The primary aim of the present descriptive, exploratory study was to assess the feasibility of a newly developed skin toxicity costs questionnaire. The secondary aims were to: (1) estimate nonmedical out-of-pocket costs, (2) examine the nature of the costs, (3) explore potential background predictors of costs, and (4) explore the relationship between patient-reported dermatologic quality of life and expenditures. METHODS: A total of 50 patients (mean age = 54.88, Stage 0-III) undergoing external beam radiotherapy completed a demographics/medical history questionnaire as well as a seven-item Skin Toxicity Costs (STC) questionnaire and the Skindex-16 in week 5 of treatment. RESULTS: Mean skin toxicity costs were $131.64 (standard error [SE] = $23.68). Most frequently incurred expenditures were new undergarments and products to manage toxicity. Education was a significant unique predictor of spending, with more educated women spending more money. Greater functioning impairment was associated with greater costs. The STC proved to be a practical, brief measure which successfully indicated specific areas of patient expenditures and need. CONCLUSIONS: Results reveal the nonmedical, out-of-pocket costs associated with acute skin toxicity in the context of breast cancer radiotherapy. To our knowledge, this study is the first to quantify individual costs associated with this treatment side effect, as well as the first to present a scale specifically designed to assess such costs. RELEVANCE: In future research, the STC could be used as an outcome variable in skin toxicity prevention and control research, as a behavioral indicator of symptom burden, or as part of a needs assessment.
PURPOSE: Acute skin toxicity is one of the most common side effects of breast cancer radiotherapy. To date, no one has estimated the nonmedical out-of-pocket expenses associated with this side effect. The primary aim of the present descriptive, exploratory study was to assess the feasibility of a newly developed skin toxicity costs questionnaire. The secondary aims were to: (1) estimate nonmedical out-of-pocket costs, (2) examine the nature of the costs, (3) explore potential background predictors of costs, and (4) explore the relationship between patient-reported dermatologic quality of life and expenditures. METHODS: A total of 50 patients (mean age = 54.88, Stage 0-III) undergoing external beam radiotherapy completed a demographics/medical history questionnaire as well as a seven-item Skin Toxicity Costs (STC) questionnaire and the Skindex-16 in week 5 of treatment. RESULTS: Mean skin toxicity costs were $131.64 (standard error [SE] = $23.68). Most frequently incurred expenditures were new undergarments and products to manage toxicity. Education was a significant unique predictor of spending, with more educated women spending more money. Greater functioning impairment was associated with greater costs. The STC proved to be a practical, brief measure which successfully indicated specific areas of patient expenditures and need. CONCLUSIONS: Results reveal the nonmedical, out-of-pocket costs associated with acute skin toxicity in the context of breast cancer radiotherapy. To our knowledge, this study is the first to quantify individual costs associated with this treatment side effect, as well as the first to present a scale specifically designed to assess such costs. RELEVANCE: In future research, the STC could be used as an outcome variable in skin toxicity prevention and control research, as a behavioral indicator of symptom burden, or as part of a needs assessment.
Authors: Julie B Schnur; Bianca Love; Bari L Scheckner; Sheryl Green; A Gabriella Wernicke; A Gabriella; Guy H Montgomery Journal: Am J Clin Oncol Date: 2011-10 Impact factor: 2.339
Authors: Benjamin D Smith; Soren M Bentzen; Candace R Correa; Carol A Hahn; Patricia H Hardenbergh; Geoffrey S Ibbott; Beryl McCormick; Julie R McQueen; Lori J Pierce; Simon N Powell; Abram Recht; Alphonse G Taghian; Frank A Vicini; Julia R White; Bruce G Haffty Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-16 Impact factor: 7.038
Authors: P S Houts; A Lipton; H A Harvey; B Martin; M A Simmonds; R H Dixon; S Longo; T Andrews; R A Gordon; J Meloy Journal: Cancer Date: 1984-06-01 Impact factor: 6.860
Authors: M Schmuth; M A Wimmer; S Hofer; A Sztankay; G Weinlich; D M Linder; P M Elias; P O Fritsch; E Fritsch Journal: Br J Dermatol Date: 2002-06 Impact factor: 9.302
Authors: Yi Hsuan Chen; Dominique Molenaar; Carin A Uyl-de Groot; Marco van Vulpen; Hedwig M Blommestein Journal: Cancers (Basel) Date: 2022-05-16 Impact factor: 6.575
Authors: Sandrine Censabella; Stefan Claes; Jolien Robijns; Paul Bulens; Jeroen Mebis Journal: Support Care Cancer Date: 2016-04-26 Impact factor: 3.603
Authors: Terence T Sio; Pamela J Atherton; Brandon J Birckhead; David J Schwartz; Jeff A Sloan; Drew K Seisler; James A Martenson; Charles L Loprinzi; Patricia C Griffin; Roscoe F Morton; Jon C Anders; Thomas J Stoffel; Robert E Haselow; Rex B Mowat; Michelle A Neben Wittich; James D Bearden; Robert C Miller Journal: Support Care Cancer Date: 2016-04-14 Impact factor: 3.603
Authors: Lorraine T Dean; Yusuf Ransome; Livia Frasso-Jaramillo; Shadiya L Moss; Yuehan Zhang; Kimlin Ashing; Gerald V Denis; Kevin D Frick; Kala Visvanathan; Kathryn H Schmitz Journal: J Cancer Surviv Date: 2019-08-24 Impact factor: 4.442
Authors: Dae Sik Yang; Jung Ae Lee; Won Sup Yoon; Nam Kwon Lee; Young Je Park; Suk Lee; Chul Yong Kim; Gil Soo Son Journal: Biomed Res Int Date: 2016-08-07 Impact factor: 3.411
Authors: Lorraine T Dean; Kathryn H Schmitz; Kevin D Frick; Lauren H Nicholas; Yuehan Zhang; S V Subramanian; Kala Visvanathan Journal: J Cancer Surviv Date: 2018-01-25 Impact factor: 4.442